Glenmark Pharmaceuticals (GPL) is planning to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes to report a growth of 18-20 percent. The company wants to increase its focus on the Indian market across four key areas, including dermatology, diabetes, cardiology and respiratory segments. The company derives about 26% of its revenues from the India, which is its second largest market.
GPL is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
